Anika Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Anika Therapeutics

29/07/2026 17:33

Anika Therapeutics Inc ANIK.OQ reported quarterly adjusted earnings of 42 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -28 cents.  The mean expectation of two analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -19 cents to 3 cents per share.
Revenue rose 15.6% to $32.61 million from a year ago; analysts expected $29.21 million. 
Anika Therapeutics Inc's reported EPS for the quarter was 24 cents​.
The company reported quarterly net income of $3.31 million.
Anika Therapeutics Inc shares had risen by 3.6% this quarter and gained 57.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 48.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is  "buy."
Wall Street's median 12-month price target for Anika Therapeutics Inc is $17.50, about 13.4% above its last closing price of $15.15
This summary was machine generated from LSEG data July 29 at 04:33 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.08
0.42
Beat
Mar. 31 2026 
-0.16
0.27
Beat
Dec. 31 2025 
-0.21
0.02
Beat
Sep. 30 2025 
-0.27
-0.16
Beat